ORIGINAL PAPER
Tumour necrosis factor, tumour necrosis factor receptor I and II and acute phase response markers in ankylosing spondylitis patients
Online publication date: 2009-03-31
Reumatologia 2009;47(1):10-14
KEYWORDS
ankylosing spondylitistumour necrosis factor atumour necrosis factor receptor Itumour necrosis factor receptor II
ABSTRACT
Ankylosing spondylitis (AS) is a chronic inflammatory, rheumatological disease affecting primarily the sacroiliac joint and vertebral column. Some clinical and laboratory parameters such as some acute reactive proteins are frequently used to determine the disease activity. Cytokines are soluble proteins that have specific roles in the inflammatory response. This study aimed to evaluate the relation between the level of some acute phase proteins such as C-reactive protein, acid a1-glycoprotein, a1-antichymotrypsin, transferrin, the cytokine tumour necrosis factor-a, and soluble receptors of tumour necrosis factor TNF-RI and TNF-RII, and the clinical findings of patients with AS compared to healthy subjects. In our study we found a correlation between TNF-α levels and AGP and OB as well as a positive correlation between TNF-RI and TNF-RII in our group of patients. We did not find any correlation between BASDAI, BASG-6, BASG-t and acute phase protein. There were also no correlations between TNF-RI and TNF-RII and BASMI and BASDAI.
REFERENCES (18)
1.
Gratacós J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-αlpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-931.
2.
Toussirot E, Lafforgue P, Boucraut J, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-180.
3.
Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999; 26: 971-974.
4.
Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966-970.
5.
Spoorenberg A, van Tubergen A, Landewé R, et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 2005; 44: 789-795.
6.
Cowling P, Ebringer R, Cawdell D, et al. C-reactive protein, ESR, and klebsiella in ankylosing spondylitis. Ann Rheum Dis 1980; 39: 45-49.
7.
Laurent MR, Panayi G. Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis 1983; 42: 524-528.
8.
Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980-984.
9.
Tutuncu ZN, Bilgie A, Kennedy LG, Calin A. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 1994; 53: 425-426.
10.
Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis 1973; 32: 354-363.
11.
Sheehan NJ, Slavin BM, Donovan MP, et al. Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 1986; 25: 171-174.
12.
Mackiewicz A, Khan MA, Reynolds TL, et al. Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing spondylitis. Ann Rheum Dis 1989; 48: 99-103.
13.
Lange U, Boss B, Teichmann J, et al. Serum amyloid A – an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000; 19: 119-122.
14.
Stone MA, Payne U, Pacheco-Tena C, Inman RD, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004; 63: 84-87.
15.
Vazquez-Del MM, Garcia-Gonzalez A, Mun~oz-Valle JF, et al. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 2002; 29: 522-526.
16.
Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-αlpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26: 211-215.
17.
Heilig B, Wermann M, Gallati H, et al. Evaluation TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Investig 1992; 70: 22-27.
18.
Heilig B, Pezzutto A, Lukoschek M, Hunstein W. Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis. Z Rheumatol 1993; 52: 383-389.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
